HRP20170359T1 - Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest - Google Patents
Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest Download PDFInfo
- Publication number
- HRP20170359T1 HRP20170359T1 HRP20170359TT HRP20170359T HRP20170359T1 HR P20170359 T1 HRP20170359 T1 HR P20170359T1 HR P20170359T T HRP20170359T T HR P20170359TT HR P20170359 T HRP20170359 T HR P20170359T HR P20170359 T1 HRP20170359 T1 HR P20170359T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- alzheimer
- treatment
- dementia
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662592P | 2012-06-21 | 2012-06-21 | |
| PCT/GB2013/051606 WO2013190302A1 (en) | 2012-06-21 | 2013-06-20 | Camsylate salt |
| EP13733415.7A EP2864316B1 (en) | 2012-06-21 | 2013-06-20 | Camsylate salt of (1r,1'R,4R)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of A[beta]-related pathologies such as e.g. Alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170359T1 true HRP20170359T1 (hr) | 2017-05-05 |
Family
ID=48746084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170359TT HRP20170359T1 (hr) | 2012-06-21 | 2013-06-20 | Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest |
Country Status (42)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| WO2016055858A1 (en) | 2014-10-07 | 2016-04-14 | Astrazeneca Ab | Compounds and their use as bace inhibitors |
| JP6546410B2 (ja) * | 2015-02-23 | 2019-07-17 | ローム株式会社 | 電力供給装置、ａｃアダプタ、ａｃチャージャ、電子機器および電力供給システム |
| AR107783A1 (es) * | 2016-03-15 | 2018-06-06 | Lilly Co Eli | Terapia de combinación |
| WO2017158064A1 (en) | 2016-03-15 | 2017-09-21 | Astrazeneca Ab | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
| WO2020183021A1 (en) | 2019-03-14 | 2020-09-17 | Astrazeneca Ab | Lanabecestat for weight loss |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| WO2002098462A1 (en) | 2001-06-01 | 2002-12-12 | Ono Pharmaceutical Co., Ltd. | Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| DE602005017129D1 (de) | 2004-03-22 | 2009-11-26 | Lilly Co Eli | Pyridyl-derivate und ihre verwendung als mglu5-rezeptorantagonisten |
| PE20070135A1 (es) | 2005-06-14 | 2007-03-09 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
| WO2007058601A1 (en) | 2005-11-21 | 2007-05-24 | Astrazeneca Ab | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| JP2009521488A (ja) | 2005-12-21 | 2009-06-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体 |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| PE20080155A1 (es) | 2006-06-12 | 2008-03-10 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil-proteasa |
| WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| WO2008092877A2 (en) | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders |
| RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| WO2009100169A1 (en) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| FR2929943B1 (fr) * | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | Sels de quinoleines 2-substituees |
| CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
| WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| MY148558A (en) | 2008-09-11 | 2013-04-30 | Amgen Inc | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| MX2011009571A (es) | 2009-03-13 | 2011-10-19 | Boehringer Ingelheim Int | Inhibidores de beta-secretasa. |
| AR077447A1 (es) | 2009-07-02 | 2011-08-31 | Astrazeneca Ab | Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas |
| UY32750A (es) | 2009-07-02 | 2011-01-31 | Astrazeneca Ab | Imidazoles sustituidos y uso de los mismos |
| JP5828848B2 (ja) | 2010-02-24 | 2015-12-09 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | ベータセクレターゼインヒビター |
| US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| US8921363B2 (en) | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
| TW201219400A (en) | 2010-09-24 | 2012-05-16 | Array Biopharma Inc | Compounds for treating neurodegenerative diseases |
| WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
| US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
-
2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/es unknown
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/zh active Pending
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 SI SI201330561A patent/SI2864316T1/sl unknown
- 2013-06-20 PL PL13733415T patent/PL2864316T3/pl unknown
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/en active Active
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/ja active Pending
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/pt active IP Right Grant
- 2013-06-20 CA CA2875589A patent/CA2875589C/en active Active
- 2013-06-20 RS RS20170236A patent/RS55815B1/sr unknown
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/en not_active Ceased
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/lt unknown
- 2013-06-20 MX MX2014014709A patent/MX354214B/es active IP Right Grant
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/xx unknown
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/ko active Active
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/ru active
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/es active IP Right Grant
- 2013-06-20 UA UAA201412619 patent/UA114196C2/uk unknown
- 2013-06-20 PT PT137334157T patent/PT2864316T/pt unknown
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 SM SM20170142T patent/SMT201700142T1/it unknown
- 2013-06-20 HR HRP20170359TT patent/HRP20170359T1/hr unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 MA MA39259A patent/MA39259B1/fr unknown
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/es active Active
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/pt active IP Right Grant
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/zh active Active
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/en not_active Withdrawn
- 2013-06-21 TW TW102122259A patent/TWI588140B/zh not_active IP Right Cessation
- 2013-06-21 TW TW106115007A patent/TWI639591B/zh not_active IP Right Cessation
-
2014
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/es unknown
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/fr unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/fr unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/es unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/es unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803A1/en unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/es unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/es unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/es unknown
-
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
-
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/es unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/es unknown
-
2017
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/me unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/el unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
-
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170359T1 (hr) | Kamsilatna sol (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njezini kristalni oblici za liječenje [beta]-povezanih patologija kao što je npr. alzheimerova bolest | |
| HRP20170723T1 (hr) | Spojevi i njihova uporaba kao inhibitora bace | |
| JP2015520221A5 (enExample) | ||
| HRP20160185T1 (hr) | Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| ME02390B (me) | Inhibitori beta sekretaze | |
| MA64013B1 (fr) | Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | |
| EA201190020A1 (ru) | Производные изоиндола в качестве ингибиторов васе и их применение | |
| CL2008002271A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson. | |
| HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
| AR075152A1 (es) | Preparacion y aplicaciones terapeuticas de (2s, 3r)-n-2-((3-piridinil)metil)-1-azabiciclo(2.2.2.)oct-3-il)-3,5-difluorobenzamida | |
| JOP20200105A1 (ar) | مركبات وطرق لتقليل التعبير الوراثي عن snca | |
| CA2850367C (en) | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | |
| HRP20191892T1 (hr) | Sublingvalna formulacija riluzola | |
| JP2019534327A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| HK1210598A1 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015500300A5 (enExample) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| HK1206348A1 (en) | Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors | |
| EP2321265A4 (en) | INOSIT- AND TREHALOSEDERIVATES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES CONTAINING THEM | |
| HRP20220701T1 (hr) | Spojeni benzazepini za liječenje touretteova sindroma | |
| FR2976285B1 (fr) | Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent | |
| CL2008000394A1 (es) | Compuestos derivados de azabicicloalcano; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos asociados a la enfermedad de alzheimer, parkinson, patologias psiquiatricas, accidentes vasculares cerebrales, sindr |